Glycomet-GP 1 Forte (Metformin/Glimepiride)

Price range: 62.00$ through 162.00$

Product Overview Glycomet-GP 1 Forte is a prescription oral antidiabetic combination produced by USV Pvt Ltd. Each strip contains ten tablets that deliver a fixed dose of 1000 mg metformin alongside 1 mg glimepiride, intended for adults with type 2 d

Pack Size	Price	Quantity
60 Tablet/s	62.00$
120 Tablet/s	96.00$
240 Tablet/s	162.00$

Estimated Delivery: Mon, Jun 22 – Wed, Jun 24

... people are viewing this right now

Guaranteed Safe Checkout

🔒 We Accept — Secure International Payment

Bank Transfer

Wire / SWIFT

Zelle

US bank transfer

Crypto

BTC / ETH / USDT

Venmo

US payment app

After placing your order, you will receive full payment details by email. Your order is dispatched within 24 hours of payment confirmation. You can also order directly via WhatsApp for the fastest service.

🚚 Worldwide Shipping — Fully Tracked & Insured

United States

Standard tracked delivery

7–14 Business Days

United Kingdom

Standard tracked delivery

5–10 Business Days

Australia

Standard tracked delivery

10–18 Business Days

Rest of World

50+ countries available

10–20 Business Days

All orders are shipped in plain, discreet packaging with no pharmacy or medicine reference outside. Tracking number is sent by email after dispatch. Shipped from Mumbai, India.

Description

Product Overview

Glycomet-GP 1 Forte is a prescription oral antidiabetic combination produced by USV Pvt Ltd. Each strip contains ten tablets that deliver a fixed dose of 1000 mg metformin alongside 1 mg glimepiride, intended for adults with type 2 diabetes who need both insulin-sensitizing and insulin-secretagogue therapy. The product is available in pack sizes of 60, 120, and 240 tablets, offering flexibility for long-term use. Packaging consists of a sealed strip with ten tablets, ensuring dose integrity and convenience. The formulation is approved for use in several countries and is listed on the WHO Model List of Essential Medicines.

What is Glycomet-GP 1 Forte

Glycomet-GP 1 Forte belongs to the class of dual-action oral hypoglycemics. Metformin, the first component, reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues. Glimepiride, the second component, stimulates pancreatic beta-cells to release more insulin. Because the two agents act through different mechanisms, the fixed-dose combination provides synergistic glucose-lowering effects while simplifying the dosing schedule. This approach can improve adherence and may achieve better HbA1c control than using either drug alone.

Uses and Benefits

Clinicians prescribe Glycomet-GP 1 Forte as an adjunct to diet and exercise for managing type 2 diabetes mellitus. The combination helps lower fasting and post-prandial glucose levels, supporting target HbA1c goals. Metformin has demonstrated cardiovascular risk reduction, while glimepiride can enhance insulin secretion over time. The fixed-dose format reduces pill burden, which is linked to higher persistence on therapy. Real-world data suggest that patients using fixed-dose combinations are about 20% more likely to stay on treatment compared with those taking separate tablets, leading to more consistent glycemic control and improved quality of life.

How It Works

The pharmacodynamics of Glycomet-GP 1 Forte involve complementary actions. Metformin activates AMP-activated protein kinase (AMPK), decreasing gluconeogenesis in the liver and increasing glucose uptake in muscle and fat. Glimepiride binds to the sulfonylurea receptor on pancreatic beta-cells, closing ATP-sensitive potassium channels and triggering insulin release. When given together, the reduction in hepatic glucose output is paired with an increase in circulating insulin, producing a more balanced post-prandial profile. Pharmacokinetic studies show that metformin is absorbed gradually over several hours, whereas glimepiride reaches peak concentrations within an hour, aligning the insulin secretory stimulus with the rise in post-meal glucose and enhancing overall control.

Dosage Guidelines

Typical initiation is one tablet daily with the evening meal to lessen gastrointestinal discomfort. The dose may be increased by 500 mg metformin or 0.5 mg glimepiride at weekly intervals, up to a maximum of 1000 mg/1 mg per day. For patients with an estimated glomerular filtration rate (eGFR) between 45 and 60 mL/min/1.73 m2, the starting dose should be halved and monitored closely for lactic acidosis. Adjustments are also needed in hepatic impairment or during acute illnesses such as infection or dehydration. Routine laboratory checks of renal function and liver enzymes are recommended during the first three months. Elderly patients often start at a lower dose and titrate more slowly to reduce hypoglycemia risk.

Side Effects

Most adverse reactions are mild and involve the gastrointestinal system, such as nausea, diarrhea, abdominal discomfort, or a metallic taste. Although rare, metformin can cause lactic acidosis, especially in individuals with compromised renal function, hypoxia, or heavy alcohol use; this condition requires immediate medical attention. Glimepiride may lead to hypoglycemia, presenting as dizziness, sweating, or confusion, particularly when combined with other glucose-lowering agents or when caloric intake is reduced. Less frequent effects include skin rash, itching, and elevated liver enzymes; regular lab monitoring is advised during the initial months of therapy. If lactic acidosis is suspected, the medication should be discontinued and the patient evaluated promptly.

Warnings and Precautions

Glycomet-GP 1 Forte is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2), acute or chronic metabolic acidosis, or known hypersensitivity to metformin or sulfonylureas. It should not be used during pregnancy or lactation unless the benefits clearly outweigh the risks, and medical supervision is essential. Concomitant use of certain drugs—such as iodinated contrast media, some anesthetic agents, or high-dose salicylates—can increase the risk of lactic acidosis and may require temporary discontinuation. Patients should avoid excessive alcohol intake and report any signs of infection, dehydration, or unexplained fatigue promptly, as these conditions can affect drug clearance. For detailed prescribing information, see the U.S. Food and Drug Administration and the National Institutes of Health resources.

FAQs

Question: What is the strength of each tablet in Glycomet-GP 1 Forte?
Answer: Each tablet contains 1000 mg of metformin and 1 mg of glimepiride, providing the fixed-dose combination indicated for type 2 diabetes.

Question: How should I store the medication?
Answer: Keep the strip at room temperature, away from moisture and heat. Do not store in the bathroom or near a stove, and keep it out of reach of children.

Question: Can I take Glycomet-GP 1 Forte with other diabetes medicines?
Answer: It is generally not recommended to combine this product with other oral hypoglycemics or insulin without medical supervision, as the risk of hypoglycemia increases.

Question: What should I do if I miss a dose?
Answer: Take the missed tablet as soon as you remember, unless it is almost time for the next scheduled dose; then skip it and continue with your regular schedule—do not double up.

Question: Are there any dietary restrictions while using Glycomet-GP 1 Forte?
Answer: No specific foods are prohibited, but a balanced diet with consistent carbohydrate intake and moderation of alcohol helps stabilize blood glucose and reduces side-effect risk.